PRDX6 Controls Multiple Sclerosis by Suppressing Inflammation and Blood Brain Barrier Disruption

Overview

Journal Oncotarget

Specialty Oncology

Date 2015 Sep 2

PMID 26327204

Citations 26

Authors

Hyung-Mun Yun

Kyung-Ran Park

Eun-Cheol Kim

Jin Tae Hong

Affiliations

Soon will be listed here.

Abstract

Multiple sclerosis (MS) is a complex disease with an unknown etiology and has no effective medications despite extensive research. Antioxidants suppress oxidative damages which are implicated in the pathogenesis of MS. In this study, we showed that the expression of an antioxidant protein peroxiredoxin 6 (PRDX6) is markedly increased in spinal cord of mice with experimental autoimmune encephalomyelitis (EAE) compared to other PRDXs. PRDX6 transgenic (Tg) mice displayed a significant decrease in clinical severity and attenuated demyelination in EAE compared to wide type mice. The increased PRDX6 expression in astrocytes of EAE mice and MS patients reduced MMP9 expression, fibrinogen leakage, chemokines, and free radical stress, leading to reduction in blood-brain-barrier (BBB) disruption, peripheral immune cell infiltration, and neuroinflammation. Together, these findings suggest that PRDX6 expression may represent a therapeutic way to restrict inflammation in the central nervous system and potentiate oligodendrocyte survival, and suggest a new molecule for neuroprotective therapies in MS.

Citing Articles

Should We Consider Neurodegeneration by Itself or in a Triangulation with Neuroinflammation and Demyelination? The Example of Multiple Sclerosis and Beyond.

Perdaens O, van Pesch V Int J Mol Sci. 2024; 25(23.

PMID: 39684351 PMC: 11641818. DOI: 10.3390/ijms252312637.

The Involvement of Glial Cells in Blood-Brain Barrier Damage in Neuroimmune Diseases.

Nagata S, Yamasaki R Int J Mol Sci. 2024; 25(22).

PMID: 39596390 PMC: 11594741. DOI: 10.3390/ijms252212323.

Unveiling the Significance of Peroxiredoxin 6 in Central Nervous System Disorders.

Xue M, Huang X, Zhu T, Zhang L, Yang H, Shen Y Antioxidants (Basel). 2024; 13(4).

PMID: 38671897 PMC: 11047492. DOI: 10.3390/antiox13040449.

The Diversity of Astrocyte Activation during Multiple Sclerosis: Potential Cellular Targets for Novel Disease Modifying Therapeutics.

Barmpagiannos K, Theotokis P, Petratos S, Pagnin M, Einstein O, Kesidou E Healthcare (Basel). 2023; 11(11).

PMID: 37297725 PMC: 10253053. DOI: 10.3390/healthcare11111585.

Peroxiredoxin 6 Regulates Glutathione Peroxidase 1-Medited Glutamine Synthase Preservation in the Hippocampus of Chronic Epilepsy Rats.

Kim J, Park H, Kang T Antioxidants (Basel). 2023; 12(1).

PMID: 36671018 PMC: 9855017. DOI: 10.3390/antiox12010156.

References

Wood Z, Schroder E, Harris J, Poole L . Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci. 2003; 28(1):32-40. DOI: 10.1016/s0968-0004(02)00003-8. View

Calabrese V, Scapagnini G, Ravagna A, Bella R, Foresti R, Bates T . Nitric oxide synthase is present in the cerebrospinal fluid of patients with active multiple sclerosis and is associated with increases in cerebrospinal fluid protein nitrotyrosine and S-nitrosothiols and with changes in glutathione levels. J Neurosci Res. 2002; 70(4):580-7. DOI: 10.1002/jnr.10408. View

Kermode A, Thompson A, Tofts P, MacManus D, Kendall B, KINGSLEY D . Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain. 1990; 113 ( Pt 5):1477-89. DOI: 10.1093/brain/113.5.1477. View

Kwon E, Prineas J . Blood-brain barrier abnormalities in longstanding multiple sclerosis lesions. An immunohistochemical study. J Neuropathol Exp Neurol. 1994; 53(6):625-36. DOI: 10.1097/00005072-199411000-00010. View

Gijbels K, Galardy R, Steinman L . Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest. 1994; 94(6):2177-82. PMC: 330042. DOI: 10.1172/JCI117578. View

Brosnan C, Battistini L, Raine C, Dickson D, Casadevall A, Lee S . Reactive nitrogen intermediates in human neuropathology: an overview. Dev Neurosci. 1994; 16(3-4):152-61. DOI: 10.1159/000112102. View

Ridet J, Malhotra S, Privat A, Gage F . Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci. 1998; 20(12):570-7. DOI: 10.1016/s0166-2236(97)01139-9. View

Sospedra M, Martin R . Immunology of multiple sclerosis. Annu Rev Immunol. 2005; 23:683-747. DOI: 10.1146/annurev.immunol.23.021704.115707. View

Jin M, Lee Y, Kim J, Sun H, Moon E, Shong M . Characterization of neural cell types expressing peroxiredoxins in mouse brain. Neurosci Lett. 2005; 381(3):252-7. DOI: 10.1016/j.neulet.2005.02.048. View

10.

Min K, Yang M, Kim S, Jou I, Joe E . Astrocytes induce hemeoxygenase-1 expression in microglia: a feasible mechanism for preventing excessive brain inflammation. J Neurosci. 2006; 26(6):1880-7. PMC: 6793633. DOI: 10.1523/JNEUROSCI.3696-05.2006. View

11.

Hauser S, Oksenberg J . The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron. 2006; 52(1):61-76. DOI: 10.1016/j.neuron.2006.09.011. View

12.

Holley J, Newcombe J, Winyard P, Gutowski N . Peroxiredoxin V in multiple sclerosis lesions: predominant expression by astrocytes. Mult Scler. 2007; 13(8):955-61. DOI: 10.1177/1352458507078064. View

13.

Ghafourifar P, Mousavizadeh K, Parihar M, Nazarewicz R, Parihar A, Zenebe W . Mitochondria in multiple sclerosis. Front Biosci. 2007; 13:3116-26. DOI: 10.2741/2913. View

14.

Wang Y, Feinstein S, Fisher A . Peroxiredoxin 6 as an antioxidant enzyme: protection of lung alveolar epithelial type II cells from H2O2-induced oxidative stress. J Cell Biochem. 2008; 104(4):1274-85. PMC: 4922305. DOI: 10.1002/jcb.21703. View

15.

Woo M, Park J, Choi I, Kim W, Kim H . Inhibition of MMP-3 or -9 suppresses lipopolysaccharide-induced expression of proinflammatory cytokines and iNOS in microglia. J Neurochem. 2008; 106(2):770-80. DOI: 10.1111/j.1471-4159.2008.05430.x. View

16.

Mahad D, Lassmann H, Turnbull D . Review: Mitochondria and disease progression in multiple sclerosis. Neuropathol Appl Neurobiol. 2008; 34(6):577-89. PMC: 2981078. DOI: 10.1111/j.1365-2990.2008.00987.x. View

17.

Belanger M, Magistretti P . The role of astroglia in neuroprotection. Dialogues Clin Neurosci. 2009; 11(3):281-95. PMC: 3181926. View

18.

Buffo A, Rolando C, Ceruti S . Astrocytes in the damaged brain: molecular and cellular insights into their reactive response and healing potential. Biochem Pharmacol. 2009; 79(2):77-89. DOI: 10.1016/j.bcp.2009.09.014. View

19.

Constantinescu C, Farooqi N, OBrien K, Gran B . Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol. 2011; 164(4):1079-106. PMC: 3229753. DOI: 10.1111/j.1476-5381.2011.01302.x. View

20.

Brosnan C, Raine C . The astrocyte in multiple sclerosis revisited. Glia. 2013; 61(4):453-65. DOI: 10.1002/glia.22443. View